Related Experiment Video
Updated: Dec 8, 2025

Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients
Published on: April 18, 2025
Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion
Nathaniel R Wilson1, Siddharth Chauhan1, Gabriel Aisenberg1
1Internal Medicine, University of Texas Health Science Center at Houston, Houston, USA.
Abstract:
Hydralazine-induced lupus syndrome (HILS) is a rare clinical entity with variable manifestations. Pericardial involvement is an uncommon but serious manifestation of the condition. In this report, we present a case of large symptomatic pericardial effusion secondary to HILS. We highlight the important considerations in the evaluation and management of this rare syndrome. HILS should be considered in the differential diagnosis for cardiac tamponade of otherwise unclear etiology in patients taking 100 mg daily or more of hydralazine for longer than three months. A temporal association between the offending drug and presenting symptoms, resolution of symptoms upon discontinuation, and a positive anti-histone antibody test can all support the diagnosis of this syndrome.
More Related Videos
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
07:41Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Heart Failure II: Pathophysiology
Rheumatic Heart Disease IV: Nursing Management
Pericarditis II: Clinical Features and Diagnostic Tests
Heart Failure Drugs: Diuretics